top of page
Backgrounds.jpg
Statesman-Examiner Logo 2025 with Shadow.png

Loading...

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oragenics Inc. Common Stock (NY:OGEN)

0.6600 -0.0211 (-3.10%)
Streaming Delayed Price Updated: 3:05 PM EDT, Apr 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Oragenics Inc. Common Stock

< Previous 1 2 3 4 Next >
BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Doses First Patient in Phase IIa Trial of Concussion Treatment
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Reports Going Concern Audit Opinion Disclosure
Via Investor Brand Network
TinyGemsBreaks – Oragenics Inc. (NYSE American: OGEN) Files 2025 Form 10-K And Provides Operational Update
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Initiates First Clinical Site for Phase IIa Trial of ONP-002 in Australia
Via Investor Brand Network
BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Explores CNS Asset Acquisitions To Expand Brain Health Pipeline
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Receives Australian Ethics Approval to Launch Phase IIa Concussion Trial
Via Investor Brand Network
BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Previews 2026 Milestones for Intranasal Concussion Therapeutic ONP-002
Via Investor Brand Network
BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Engages DUCK FLATS Pharma for IND Readiness and Regulatory Execution
Via Investor Brand Network
BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Participates in SCOPE Summit 2026 Ahead of Phase 2a Concussion Trial
Via Investor Brand Network
BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) to Present at Sequire Investor Summit 2026
Via Investor Brand Network
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Regains NYSE Compliance, Advances Toward First Clinical Trial and Expands AI-Driven Neurology Pipeline
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Oragenics Q3 2025 Shareholder Update
From Oragenics, Inc.
Via Business Wire
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Regains NYSE Compliance, Strengthens Balance Sheet for Clinical Advancement
Via Investor Brand Network
News headline image
Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
From Oragenics, Inc.
Via Business Wire
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Partners with Receptor.AI to Accelerate AI-Driven Discovery of Brain-Targeted Therapeutics
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development
From Oragenics
Via Business Wire
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Highlights Q2 2025 Progress and Prepares for Phase IIa Concussion Trial
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Selects Southern Star Research as CRO for Phase IIa Trial of Intranasal Concussion Therapy ONP-002
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Secures U.S. Manufacturing Partner Ahead of Phase IIb Trials for Concussion Drug
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Secures $16.5 Million in Preferred Stock Offering to Advance Intranasal Concussion Therapy
Via Investor Brand Network
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Announces $20 Million Preferred Stock and Warrant Offering
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) to Spotlight Concussion Candidate at BIO 2025 and Neurotrauma Symposium
Via Investor Brand Network
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Sets 1-for-30 Reverse Stock Split Effective June 3
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Secures Australian Approval to Launch Phase II Concussion Trial
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) to Host May 20 Webinar on Concussion Drug Program ONP-002
Via Investor Brand Network
News headline image
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Submits Protocol for Phase II Concussion Trial in New Zealand
Via Investor Brand Network
News headline image
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Highlights Intranasal Drug Delivery at Boston Summit
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. Highlights Q1 Milestones and Prepares for Concussion Drug Trial
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. Files 2024 Annual Report, Addresses Going Concern Status
Via Investor Brand Network
BioMedNewsBreaks — Oragenics Inc. Advances Concussion Treatment with Phase II Trial Preparation
Via Investor Brand Network
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page